Radiopharm Theranostics (RADX) Stock Price, News & Analysis

Company Overview

Radiopharm Theranostics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types. Radiopharm Theranostics collaborates with academic centers and contract development and manufacturing organizations to advance candidates from preclinical studies through clinical trials, with an emphasis on safety, efficacy and scalable production.

Headquartered in Alpharetta, Georgia, Radiopharm Theranostics conducts operations in the United States and is positioning itself for expansion into select international markets. Its management team brings together professionals with deep expertise in radiopharmaceutical chemistry, nuclear medicine and oncology drug development, underscoring the company’s commitment to advancing next-generation diagnostic and therapeutic solutions.

Key Stats

• Today's Range: $5.33 to $5.79
• 50-Day Range: $5.02 to $7.54
• 52-Week Range: $3.50 to $50.82
• Volume: 22,294 shs
• Average Volume: 28,222 shs
• Market Capitalization: $42.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

Radiopharm Theranostics Stock Analysis - MarketRank™

Radiopharm Theranostics scored higher than 67% of companies evaluated by MarketBeat, and ranked 517th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Radiopharm Theranostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Radiopharm Theranostics has a consensus price target of $15.00, representing about 181.4% upside from its current price of $5.33.

Amount of Analyst Coverage

Radiopharm Theranostics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Radiopharm Theranostics has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.44% of the outstanding shares of Radiopharm Theranostics have been sold short.

Short Interest Ratio / Days to Cover

Radiopharm Theranostics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Radiopharm Theranostics has recently decreased by 22.00%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Radiopharm Theranostics does not currently pay a dividend.

Dividend Growth

Radiopharm Theranostics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.44% of the outstanding shares of Radiopharm Theranostics have been sold short.

Short Interest Ratio / Days to Cover

Radiopharm Theranostics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Radiopharm Theranostics has recently decreased by 22.00%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

Radiopharm Theranostics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Radiopharm Theranostics this week, compared to 1 article on an average week.

Search Interest

5 people have searched for RADX on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added Radiopharm Theranostics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Radiopharm Theranostics insiders have not sold or bought any company stock.

RADX Stock Analysis - Frequently Asked Questions

How have RADX shares performed this year?

Radiopharm Theranostics' stock was trading at $4.00 at the start of the year. Since then, RADX shares have increased by 33.3% and is now trading at $5.33.

How do I buy shares of Radiopharm Theranostics?

Shares of RADX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 10/24/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: NASDAQ:RADX
• CIK: 1949257
• Web: www.radiopharmtheranostics.com
• Phone: 61-3-9824-5254
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Radiopharm Theranostics: $15.00
• High Price Target: $18.00
• Low Price Target: $12.00
• Potential Upside/Downside: +181.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.67
• Quick Ratio: 2.67

Sales & Book Value

• Annual Sales: $2.35 million
• Price / Sales: 17.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.52 per share
• Price / Book: 1.51

Miscellaneous

• Outstanding Shares: 7,880,000
• Free Float: N/A
• Market Cap: $42.00 million
• Optionable: N/A
• Beta: N/A